FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | Sample | Privacy
Related Topics >> Ranbaxy

Daiichi wants payback for Ranbaxy fixes

Tools

Despite manufacturing mishaps that ultimately blocked some 30 Ranbaxy drugs from U.S. sales for the last year and a half, Japanese parent Daiichi Sankyo maintains great expectations of the generics-maker. Daiichi president Takashi Shoda says not only that he expects the FDA import ban to be lifted by 2012, but that the Indian subsidiary will serve up 23 percent of the aggressive Japanese pharma's earnings that same year, rising from 15 percent today--that's 270 billion yen, rising from 148 billion yen.

The regulatory waters started getting hot for Ranbaxy in 2008 on its home turf: manufacturing defects at its Paonta Sahib and Dewas facilities in India were compounded by falsified data, eventually led to the import ban. More recently, Ranbaxy's U.S.-based unit, Ohm Laboratories in Gloversville, NY, went several rounds with the FDA, which ultimately described the drugmaker's corrective actions "inadequate," as we've reported.

The company showed some seriousness at getting its act together when it pulled in high-end consultancy PRTM to get things moving at Ohm, and when Daiichi Sankyo sent a QC exec to Ranbaxy.

The FDA is "troubled" by Ranbaxy's manufacturing and data integrity issues, according to a New York Times article, and promises to focus on the company until "fully satisfied" with the quality of its drugs and the integrity of its data." Daiichi Sankyo and Ranbaxy executives have put together a joint task force to make sure quality-control systems are in place and will improve, she said.

- here's a press report
- see the NYT article

Related Articles:
Ranbaxy teeters on Caraco-ism
Ranbaxy, FDA in warnings dance
FDA orders Ranbaxy to reassess operations
Ongoing FDA issues aren't stopping Ranbaxy


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Manufacturing Email Newsletter:
Comments (1) | Post a comment
More stories about Ranbaxy  

Comments

The situation or rather the fiasco at Ranbaxy is self created. If the company is not willing to take strict action on de-faulter for reason known to Ranabxy itself, it is infact giving a signal to committed and dedicated employess to cross the
limit and nothing will happen to you. The defaulted Employees still enjoys the patronage of incompetent HR. The situation is getting bad to worse and wonder why DS is not able to see a clear murder of the well established company.
The moral of the old employess who have nurtured the company for many years are so low and shocking. Something must be done to teach defaulters sitting pretty at high post a lesson , either by sacking or committment to mend their ways. it this is not happened immediately, nothing can prevent this company from sinking and untimately a unnatural death for ever.

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.